As a former Mayo Clinic researcher, W. Ray Kim, M.D., continues to collaborate with Mayo Clinic investigators on active studies centered on liver disease and liver transplantation. Specifically, Dr. Kim is interested in outcome analysis in liver disease and liver transplantation as well as viral hepatitis.
- Outcomes analysis. Dr. Kim's outcomes analysis program evaluates the outcomes of patients with end-stage liver disease with or without liver transplantation. His research team developed the Model for End-Stage Liver Disease (MELD), which is used as a standard of liver disease severity in allocation of donated livers for transplantation. Dr. Kim's outcomes analysis program continues to research means to improve the accuracy of MELD.
- Epidemiology and outcome of viral hepatitis. Dr. Kim's research in this area focuses specifically on hepatitis B and C, both of which are common chronic bloodborne infections in the United States. His projects on hepatitis C address epidemiology and outcome of the infection. His work on hepatitis B is more clinical, and includes clinical trials.
Significance to patient care
The goal of Dr. Kim's outcomes research is to understand the end result of disease processes and medical interventions from the patient and societal perspective.